Table of Content

16 January 2022, Volume 40 Issue 2

Previous Issue    Next Issue

To observe the clinical effect of Wucao Qingquan Decoction combined with western medicine on acute pyelonephritis

PENG Hong-ping

2022, 40(2):  1-3. 

Asbtract ( 212 )   PDF (1973KB) ( 51 )  

References | Related Articles | Metrics

Objective To analyze the clinical effect of Wucao Qingquan Decoction combined with western medicine in the treatment of acute pyelonephritis. Methods A total of 100 patients with acute pyelonephritis who were treated in the nephrology department of Tai’an Traditional Chinese Medicine Hospital from December 2018 to December 2019 were selected and divided into the experimental group and the conventional group by random number table method, with 50 cases respectively. The conventional group was treated with western medicine, and the experimental group was treated with Wucao Qingquan Decoction on the basis of the conventional group. The clinical treatment efficiency, the changes of urea nitrogen, serum creatinine and 24-hour urinary protein before and after treatment in the two groups were compared and analyzed. Results The total effective rate of the experimental group was higher than that of the conventional group, with homogeneity between groups（P<0.05）. Before treatment, there was no difference in the changes of urea nitrogen, serum creatinine and 24-hour urinary protein between the two groups（P>0.05）; after treatment, the urea nitrogen, serum creatinine and 24-hour urinary protein of the experimental group were lower than those of the conventional group, with significant difference（P<0.05）. Conclusion For acute pyelonephritis, Wucao Qingquan Decoction combined with western medicine can relieve clinical symptoms, and the clinical effect is significant.

Study on the clinical efficacy and safety of entecavir combined with liraglutide in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes

ZHANG Ya-Nan, LI Jing

2022, 40(2):  3-6. 

Asbtract ( 321 )   PDF (1974KB) ( 52 )  

References | Related Articles | Metrics

Objective To observe the clinical efficacy and safety of entecavir combined with liraglutide in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes. Methods One hundred patients with hepatitis B cirrhosis and liver-derived diabetes were divided into a test group（routine treatment + Entecavir + liraglutide treatment） and a control group（routine treatment and liraglutide） with a random number table method, each with 50 cases. We were admitted to our hospital from May 2018 to May 2019. By analyzing the liver function, blood glucose level, and incidence of adverse reactions of patients before and after treatment, the clinical efficacy and safety of different drugs in the treatment of patients with hepatitis B cirrhosis and hepatogenic diabetes were evaluated. Results After treatment, the levels of direct bilirubin（DBIL）, alanine aminotransferase（ALT）, aspartate aminotransferase（AST）, and total bilirubin（TBiL） of the subjects showed a downward trend, and the test group was significantly lower than the control group（P<0.05）; After treatment, the levels of glycosylated hemoglobin（HbA_1c）, fasting blood glucose（FBG）, and 2 h postprandial blood glucose（2 hPBG） of the subjects showed a downward trend. The test group was significantly lower than the control group（P<0.05）. There was no significant difference in incidence ofadverse reactions between the two groups（P>0.05）. Conclusion The administration of entecavir and liraglutide can reduce the adverse reactions and blood glucose, and improve the antiviral effects, liver function and treatment safety. This method is worthy of clinical application and promotion.